Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9525557 | 0.87 | MAPK1 (0.51) | MAPK1HTTRPS6KA5ATMDRD1 | |
| SCHEMBL9868648 | 0.87 | MAPK1 (0.51) | MAPK1HTTRPS6KA5ATMDRD1 | |
| SCHEMBL9611693 | 0.87 | MAPK1 (0.67) | MAPK1HTTALDH1A1HSD17B10ALOX12 | |
| SCHEMBL10054042 | 0.87 | DRD1 (0.53) | MAPK1HTTDRD1 | |
| SCHEMBL9869013 | 0.85 | MAPK1 (0.49) | MAPK1HTTATMDRD1KDM4E | |
| SCHEMBL9524668 | 0.85 | HSD17B10 (0.55) | MAPK1HTTHSD17B10SMN1; SMN2 | |
| SCHEMBL2077744 | 0.84 | DRD1 (0.48) | MAPK1HTTDRD1 | |
| SCHEMBL9335272 | 0.84 | DRD1 (0.51) | MAPK1HTTDRD1 | |
| SCHEMBL16036764 | 0.83 | RPS6KA5 (0.52) | MAPK1HTTALDH1A1RPS6KA5ATM | |
| SCHEMBL7505146 | 0.82 | HSD17B10 (0.59) | MAPK1HTTALDH1A1HSD17B10DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044033-B1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2012-02-08 | — | — | EP | claimed |
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | US | claimed |
| EP-2044033-A1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2009-04-08 | — | — | EP | claimed |
| WO-2008009348-A1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | WO | claimed |
| EP-1878724-A1 | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | sanofi-aventis (FR) | 2008-01-16 | — | — | EP | claimed |
| US-12247027-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-11 | — | — | US | disclosed |
| US-20240116930-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-11 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20220213095-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-07 | — | — | US | disclosed |
| US-20220213095-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-07 | — | — | US | disclosed |
| US-8188282-B2 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188282-B2 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2044033-B1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2012-02-08 | — | — | EP | disclosed |
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | US | disclosed |
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | US | disclosed |
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | US | disclosed |
| EP-1878724-A1 | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | sanofi-aventis (FR) | 2008-01-16 | — | — | EP | disclosed |
| EP-1878724-A1 | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | sanofi-aventis (FR) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247027-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | MAPK1 1476/4885HTT 2817/4885ALDH1A1 1628/4885 |
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | DDT, NIT2, PADI1 | MAPK1 3566/4885HTT 2283/4885ALDH1A1 182/4885 |
| US-11820770-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | MAPK1 1476/4885HTT 2817/4885ALDH1A1 1628/4885 |
| US-20220213095-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | MAPK1 1476/4885HTT 2817/4885ALDH1A1 1628/4885 |
| US-20240116930-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | MAPK1 1476/4885HTT 2817/4885ALDH1A1 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.